Trial Profile
Randomised Controlled Trial Evaluating Strategies to Optimize Disease Activity Control in RA Patients Treated With Infliximab in Clinical Practice
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms RE-CUBE
- Sponsors Integrated Therapeutics Group; Merck Sharp & Dohme; Schering-Plough
- 15 Jun 2019 This trial has been completed in France, according to European Clinical Trials Database.
- 09 Jun 2019 Trial has been completed in Netherlands according to European Clinical Trials Database record.
- 03 Jul 2012 Additional trial locations added as reported by European Clinical Trials Database record.